# A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)

> **NCT00874939** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 4 (actual)

## Conditions studied

- Alzheimer's Disease
- Dementia

## Interventions

- **DRUG:** MK-0249 7.5 mg
- **DRUG:** MK-0249 25 mg
- **DRUG:** Donepezil 5mg
- **DRUG:** Placebo to MK-0249
- **DRUG:** Placebo to Donepezil

## Key facts

- **NCT ID:** NCT00874939
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04-06
- **Primary completion:** 2009-04-20
- **Final completion:** 2009-04-20
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00874939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00874939, "A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00874939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*